La Jolla Pharmaceutical’s Marketing Authorization Application (MAA) has been accepted for review by the EMEA for potential approval to market Riquent, its drug candidate for lupus renal disease, in the EU. If approved, Riquent will receive marketing authorization in all 25 EU member states as well as Norway, Iceland and Liechtenstein. Riquent has already received orphan medicinal product designation in Europe, which will provide 10 years of market exclusivity from the date of EU autho...